Early functional changes and plasma GFAP in Swedish families with Autosomal Dominant Alzheimer’s disease mutations

dc.contributor.authorLuckett, Emma S.
dc.contributor.authorZapater-Fajari, Mariola
dc.contributor.authorAlmkvist, Ove
dc.contributor.authorJohansson, Charlotte
dc.contributor.authorChiotis, Konstantinos
dc.contributor.authorBucci, Marco
dc.contributor.authorWall, Anders
dc.contributor.authorAshton, Nicholas J.
dc.contributor.authorBlennow, Kaj
dc.contributor.authorZetterberg, Henrik
dc.contributor.authorRodriguez-Vieitez, Elena
dc.contributor.authorGraff, Caroline
dc.contributor.authorNordberg, Agneta
dc.contributor.organizationfi=tyks, vsshp|en=tyks, varha|
dc.contributor.organizationfi=PET-keskus|en=Turku PET Centre|
dc.contributor.organization-code1.2.246.10.2458963.20.14646305228
dc.converis.publication-id508963278
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/508963278
dc.date.accessioned2026-04-24T15:53:36Z
dc.description.abstract<p>We aimed to understand longitudinal associations between Alzheimer’s disease (AD) biomarkers in Autosomal Dominant AD (ADAD) across estimated years to symptom onset (EYO). Forty-five individuals (19 mutation carriers [EYO = −7.9 ± 11.7 years, <em>APP</em> N = 11; <em>PSEN1</em> N = 8]) from Swedish ADAD families participated. All received baseline 18F-Flurodeoxyglucose (FDG) PET and cognitive testing, and a subset (N = 26) plasma glial fibrillary acidic protein (GFAP) measurement. Follow-up data collection (including 106 FDG scans) was performed over 7.4 ± 6.4 years (visits ranged from 1–5, EYO = −25.8 to +10.3 years in mutation carriers). Mixed effects models were applied to determine longitudinal associations. <em>APP</em> and <em>PSEN1</em> mutation carriers showed different FDG uptake profiles from EYO = −20 to −10 years, with a hypermetabolism before hypometabolism in <em>PSEN1</em> mutation carriers. Early increases in plasma GFAP were primarily related to subcortical FDG decreases and cognitive changes in <em>APP</em> mutation carriers compared to non-carriers. We provide evidence for gene-dependent biomarker trajectories in ADAD.<br></p>
dc.identifier.eissn2158-3188
dc.identifier.urihttps://www.utupub.fi/handle/11111/58590
dc.identifier.urlhttps://doi.org/10.1038/s41398-026-03829-6
dc.identifier.urnURN:NBN:fi-fe2026022315409
dc.language.isoen
dc.okm.affiliatedauthorBucci, Marco
dc.okm.affiliatedauthorDataimport, tyks, vsshp
dc.okm.discipline3124 Neurology and psychiatryen_GB
dc.okm.discipline3124 Neurologia ja psykiatriafi_FI
dc.okm.internationalcopublicationinternational co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherSpringer Science and Business Media LLC
dc.publisher.countryUnited Kingdomen_GB
dc.publisher.countryBritanniafi_FI
dc.publisher.country-codeGB
dc.relation.articlenumber67
dc.relation.doi10.1038/s41398-026-03829-6
dc.relation.ispartofjournalTranslational Psychiatry
dc.relation.volume16
dc.titleEarly functional changes and plasma GFAP in Swedish families with Autosomal Dominant Alzheimer’s disease mutations
dc.year.issued2026

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
s41398-026-03829-6.pdf
Size:
2.04 MB
Format:
Adobe Portable Document Format